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The following on the natural history of Barrett’s esophagus (BE) includes commentary on histological sequences of
the development of Barrett mucosa; the transformation of esophageal cells from squamous to columnar phenotype;
the stages of natural history of dysplasia; the difficulties of predicting progression of dysplasia to adenocarcinoma;
the preferable biopsy protocols; the role of Helicobacter pylori infection and gastric atrophy in the risk of BE; the
value of decrease of proton pump inhibitor efficacy following eradication of H. pylori; the place of antireflux surgery
in the natural history of BE; the newest procedures for the endoscopic detection of early neoplasia; and the essential
importance of a good understanding of the natural history for the best management of high-grade dysplasia.
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Concise summaries
• The natural history of Barrett’s esophagus (BE)
with high-grade dysplasia (HGD) remains an
enigma.
• Some patients have developed adenocarcinoma
very rapidly after the diagnosis of the first HGD.
Others have waxed and waned for years, with
some regressing to lesser grades of dysplasia,
some regressing to no dysplasia (ND), and still
some others just living happily with continued
HGD.
• It can be assumed that every esophageal mu-
cosa in Barrett’s patients started as out as nor-
mal squamous mucosa that was then severely
damaged by reflux of acid, duodenal contents,
or both. From a molecular and genetic stand-
point, we know a great deal about the changes
that occur once Barrett’s mucosa has developed
during the dysplasia to carcinoma sequence, but
we have hardly any information on comparable
genetic and molecular changes in the squamous
mucosa that turns it into columnar.
• Despite decades of research, current manage-
ment of esophageal adenocarcinoma (EA) is still
inadequate because at-risk patients are rarely
identified. However, it now seems possible to
develop a clinical risk classification tool that
can probably be further refined and improved
using molecular characterization including ge-
netic and epigenetic alterations of early disease.
• Since it is present and to full length on the initial
endoscopy, it can be inferred that BE phenotype
is generated early in the course of disease. It is
also a silent lesion even when exposed to high
levels of pathologic acidity, which supports the
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view that BE is a form of “adaptive protection”
for the defense of the host against ongoing acid
damage to the esophageal wall.
• There is good evidence that has shown that mu-
cosal irregularity, nodules, and ulcers with the
Barrett’s segment are highly associated with the
presence of dysplasia and/or cancer. Thus, close
scrutiny of the Barrett’s segment to identify sur-
face irregularity and getting targeted biopsies
from those areas is extremely important before
embarking on 4-quadrant biopsies lest those
landmarks get obliterated by blood during sam-
pling. Confocal laser endomicroscopy is a revo-
lutionary technique that images subcellular tis-
sue in real time (virtual biopsy). However, it
samples only a highly limited surface area, is
time consuming, and early reports to date have
not shown it to be better than standard biopsy
protocol.
• The trimodal endoscopic protocol requires a
specialized material restricted to some reference
centers, and random biopsies are still recom-
mended in asymptomactic patients with BE for
the detection of neoplasia in Western countries.
In Japan, the detection of suspicious areas at the
surface of the mucosa is completed by charac-
terization through categories of the pit pattern
and vascular pattern, and the best method of
detection of flat areas of neoplasia relies on a
bimodal HRE-NBI protocol coupled to magnifi-
cation.
• Epidemiologic data suggest that a subset of
Helicobacter pylori–infected patients may ex-
perience a lower risk of Barrett’s carcinoma
and, altogether, studies suggest that gastric at-
rophy associated with H. pylori infection may
be responsible for the inverse association with
esophageal disease. However, a negative asso-
ciation has been found in patients without at-
rophic gastritis, and H. pylori infection may in-
crease gastric secretion in patients with antral
gastritis.
• There are no studies to define whether H. pylori
eradication worsens or improves BE after H. py-
lori eradication, but indirect evidence suggests
that a potential decrease of proton pump in-
hibitor (PPI) efficacy should not preclude the
indication for eradication.
• Even though antireflux surgery seems to bet-
ter promote regression of BE or dysplasia than
medical therapy, it has not demonstrably re-
duced the incidence rate of adenocarcinoma.
• The wise management of HGD is based on un-
derstanding that there is variability in the di-
agnosis of HGD by pathologists. At present,
endoscopic mucosal resection therapy with or
without radiofrequency ablation appears to be
reasonable therapy for HGD or early esophageal
carcinoma. Research data also favor the use of
radiofrequency ablation compared to photody-
namic therapy because of fewer complications
and better efficacy.
1. What is proof that Barrett’s mucosa




Someone must know the answer to this question, so
I tried to find out who, and I felt that it was wise
to start by asking the experts. To quote Kahrilas
and Pandolfino, two acknowledged esophageal ex-
perts writing in a major gastroenterology textbook,
“while the cause of Barrett’s metaplasia is uncer-
tain, it is clearly associated with gastroesophageal
reflux disease (GERD) and believed to occur as
a consequence of excessive esophageal acid expo-
sure.”1 According to Spechler, Fitzgerald, Prasad,
and Wang, four more acknowledged esophageal ex-
perts, “long-segment BE is associated with GERD
and the epithelial metaplasia characteristic of BE is
widely regarded as a consequence of GERD.”2 Ac-
cording to the website of the Society of Thoracic
Surgeons, “the exact reasons for the development of
BE are unknown. Most physicians believe that the
damage to the squamous mucosa, which leads to
the development of BE is caused by chronic reflux
of acid or other stomach contents.”3
Therefore, we assume that every esophageal mu-
cosa in Barrett’s patients started out as normal
squamous mucosa that was then severely dam-
aged by reflux of acid, duodenal contents, both, or
something else. The damaged squamous epithelium
somehow was prevented from regenerating, and,
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instead, it was replaced by metaplastic columnar
epithelium. One problem with this concept is that
we pathologists commonly see significant damage to
esophageal squamous mucosa in biopsies, including
ulcers and erosions, and what we always see is regen-
erating squamous epithelium rather than replace-
ment of the squamous epithelium by metaplastic
columnar epithelium.
From a molecular and genetic standpoint, we
know a great deal about the changes that occur once
Barrett’s mucosa has developed during the dysplasia
to carcinoma sequence.2 However, we have hardly
any information on comparable genetic and molec-
ular changes in the squamous mucosa that turns it
into columnar.
There are some studies using in vitro esophageal
squamous mucosal tissue or squamous cell cultures
that indicate that acid and/or bile induce colum-
nar type changes in these systems.2 In one such
study, CDX2, an intestinal differentiation factor,
was upregulated in cultured squamous cells. In an-
other study, the expression of CDX1, also an in-
testinal differentiation factor, was induced in cul-
tured squamous cells. In a third study, there was
increased BMP4 expression in stromal cells, which
led to columnar cell keratin expression in the squa-
mous cells. Then there was a study that indicated
that there was upregulation of HB/EGF in lamina
propria fibroblasts under damaged squamous ep-
ithelium, which promoted CDX2 in the squamous
cells.
Thus, there are changes in squamous cells in-
duced by reflux-type substances that might stimu-
late columnar metaplasia in the squamous mucosa
in the laboratory, but we need to know if these fac-
tors actually cause this metaplasia in people. We
can manipulate dog esophagi and gastro-esophageal
junctions to produce columnar mucosa in the distal
esophagus in response to acid, but these are ani-
mal models, and we don’t have a comparable model
in people. Therefore, we have some hints of the
molecular and genetic determinants that might turn
squamous cells into columnar cells in experimental
models, but we do not know if these are the same
determinants that work in people with Barrett’s mu-
cosa. We also have not identified the progenitor cells
that lead to columnar metaplasia following dam-
age to squamous epithelium. Presumably these are
some type of stem cells, but we don’t know that for
a fact.
To summarize, Barrett’s mucosa does occur. Epi-
demiologic evidence suggests that reflux of gas-
tric acid and/or duodenal contents is important
in its development. These reflux-type substances
can produce molecular and genetic alterations in
esophageal squamous cells in the laboratory, but
we have no direct evidence that these substances
cause columnar metaplasia of squamous mucosa in
people.
2. In GERD patients, can the risks factors
for development of Barrett’s mucosa be
determined? Is it possible to envisage a
clinical risk classification tool?
Asad Umar
asad.umar@nih.gov
While the overall incidence and mortality rate of
many cancers have declined in recent years, the inci-
dence of esophageal adenocarcinoma (EA) has con-
tinued to rise. EA incidence has increased in the
last three decades more than 600% in men aged 65
years and older and, notwithstanding progress in
multimodality therapies, the overall five-year sur-
vival rate is still estimated at 15%.4,5 It is estimated
that more than 16,000 new cases of EA will be diag-
nosed in the United States alone in 2010. Further-
more, esophagectomy with or without neoadjuvant
radiation therapy often incurs early postoperative
complications and devastating long-term functional
abnormalities. Likewise, medical therapies are still
highly toxic, and remain unsatisfactory in response
duration and overall survival benefit. The comple-
tion of any therapy for EA is most often followed by
tumor recurrence or distant metastasis that leads to
severe morbidities and eventual death. The natural
course of the disease is insidious and debilitating, be-
coming clinically apparent only in advanced stages
that are refractory to treatment and are resource
intensive. Effective cancer preventive measures will
benefit not only affected individuals but also the
public at large.
Histologically, EA is thought to arise from the in-
jury of the esophageal mucosa by frequent reflux of
gastric contents that result in a sequence of meta-
plasia to low-grade dysplasia (LGD), HGD, and car-
cinoma. The metaplasia to dysplasia phase of this
sequence is known as BE. BE is diagnosed in ap-
proximately 10% of patients who are referred to
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endoscopy for GERD symptoms.6,7 BE, the only
widely accepted precursor lesion to EA, is defined
as the replacement of the normal squamous epithe-
lium of the distal esophagus by columnar epithe-
lium with intestinal metaplasia. Patients with BE
are at least 30 times more likely to develop EA than
patients without BE.
Currently, chronic GERD patients are screened
for BE and, if diagnosed to have BE, they are sub-
jected to endoscopic surveillance. Studies demon-
strate that patients with malignancy detected at
surveillance endoscopy have cancers at an earlier
stage and better survival than those with no surveil-
lance. The value of surveillance, however, is ques-
tioned by other studies demonstrating that only
about 60% of patients diagnosed with EA have a
prior diagnosis of GERD and less than 5% have
BE. Furthermore, although the increased risk of
EA in BE patients has been observed consistently,
only 0.5% of endoscopically monitored BE patients
progress to EA per year (with the HGD patients
progressing at an annual rate of 5–20%). These
findings suggest that despite decades of research,
current management of EA neoplasia is still in-
adequate because at-risk patients are rarely iden-
tified. Moreover, criteria for screening and endo-
scopic surveillance still need to be established in
a randomized trial. Given the threat of a highly
lethal cancer, both patients and physicians typi-
cally opt for the most aggressive strategies for treat-
ment and surveillance even with procedure-related
risks.
Clinical risk classification tools need to be devel-
oped for better management of GERD of patients.
Age, ethnicity, tobacco and/or alcohol use, obesity,
and family history make for risk factors for GERD.
It is estimated that over 60 million report heartburn
or acid indigestion at least one time per month in
the United States alone. Over 15 million individuals
experience heartburn daily and frequent heartburns
(two or more times per week) may be associated with
GERD. This is significant, as approximately 10% of
GERD patients develop BE, which eventually is a risk
factor for esophageal cancer.3,4 Gerson et al. used a
multiple logistic regression analysis to predict BE
using age, ethnicity, gender, dysphagea, heartburn,
nausea, belching, nocturnal pain, odynophagi, and
pain relief with food intake.8 Therefore, using a scale
of 0–550 total points, a score of 397.4 or higher
was strongly associated with an increased risk of BE
while 351.3 for lower risk. This demonstrates that
it is possible to develop a clinical risk classification
tool, and it can probably be further refined and im-
proved using molecular characterization including
genetic and epigenetic alterations of early disease.
3. Can it be stated that BE follows a
phenotypic presentation model in the
natural history of GERD?
Roy C. Orlando
roy orlando@med.unc.edu
The question posed in the title can be more
succinctly stated as, “does BE evolve from
GERD?” The answer succinctly stated is, “probably,
yes!”
The case in support of this conclusion is based on
the following observations:
• BE is more common in GERD (∼10%) than
in the general population, which has been esti-
mated by a Swedish study to be in the range of
1.6%.9
• BE is located in the distal esophagus and associ-
ated with exposure of the region to pathologic
levels of acid and bile reflux.
• BE exhibits a pattern of growth that appears
to parallel those of reflux damage to the distal
esophageal epithelium.
• BE has been reported to appear in areas of ero-
sive esophagitis that biopsy did not previously
show had evidence for its presence.
• BE has been observed to emerge in the proximal
esophagus above an esophagogastric anastamo-
sis following esophagectomy for BE.10
• BE has been observed to emerge in the esopha-
gus of animal models of reflux-induced dam-
age to native esophageal stratified squamous
epithelium.11 Further, and consistent with this
in vivo data, are the observations in vitro that
esophageal squamous cells exposed to acid
and/or bile salts can express CDX2, a gene that
favors transformation from squamous to the
columnar phenotype.12
• The esophageal stratified squamous epithelium
above BE has been reported to exhibit the lesion
of dilated intercellular spaces.13 This lesion is
notable for being a feature of acid injury to
both animal and human esophageal squamous
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epithelium, and a histopathological correlate of
the symptom of heartburn in GERD.
• When refluxate acidity is reduced by treatment
with PPIs, islands of squamous epithelium reap-
pear within regions of BE; and when reduced
by PPI therapy, areas of distal esophagus from
which BE has been ablated are repaired by
a (neo)-squamous epithelium that phenotypi-
cally resembles the native esophageal squamous
epithelium.
The three observations that prevent full accep-
tance of this concept include the fact the majority
of patients with Barrett’s have never been diagnosed
with GERD before the diagnosis of BE; the fact that
a significant number of those with BE are asymp-
tomatic and have never had a history of GERD; and
the fact that on endoscopy and irrespective of the
presence or degree of active esophagitis, BE presents
at its full length, a length that neither significantly
increases nor decreases over time.
In summary, the weight of the evidence is that BE
arises as a consequence of GERD. Since it is present
and full length at the initial endoscopy, it can be
inferred that BE phenotype is generated early in
the course of disease, and, further, because there
are large disparities in the frequency of BE among
different ethnicities. The appearance of BE requires
an inherent host susceptibility. BE is also a silent
lesion even when exposed to high levels of patho-
logic acidity, which supports the view that BE is a
form of “adaptive protection” for the defense of the
host against ongoing acid damage to the esophageal
wall.
4. Current knowledge on the natural
history of Barrett’s dysplasia regarding the
best management of patients with HGD
Stephen J. Sontag
sontagsjs@aol.com
The natural history of BE with HGD remains an
enigma. Some patients have developed adenocar-
cinoma very rapidly after the diagnosis of the first
HGD. Others have waxed and waned for years, with
some regressing to lesser grades of dysplasia, some
regressing to ND, and still some others are living
happily with continued HGD. We present unpub-
lished data on two flat Barrett’s HGD patients with
completely different courses during observation pe-
riods ranging from 9 to 18 years.
Patient number 1 was 63 years old when he was
diagnosed with HGD at the first esophagogastro-
duodenoscopy (EGD). For the next 15 years, his
course was as follows (Fig. 1, patient 1):
• 37 EGDs,
• 1,455 histologic specimens, and
• 43% of the 1,455 specimens had HGD.
After 15 years of continuous flat HGD, a small
nodule developed and AdCa appeared for the first
time. For the subsequent two years, Patient number
1 was treated with various ablative procedures. He
is currently doing well at the age of 80.
Patient number 2 was a 66-year-old white male
when he was diagnosed with HGD at two outside
hospitals. In a three-month period, he was diag-
nosed with EGD by three different endoscopists
at two different hospitals. HGD was diagnosed
by three different pathologists. The patient self-
referred himself to our hospital. After his initial di-
agnosis of HGD at the outside hospitals, his course
for the next 11 years at our institution was as
follows (Fig. 1, patient 2):
• 15 EGDs;
• 259 histologic specimens demonstrating either
ND or no intestinal metaplasia; and
• absolutely no specimens demonstrating LGD,
HGD, or AdenoCa.
This patient demonstrates the exact opposite of
our first patient. After being diagnosed with HGD at
three outside clinics (histologic samples confirmed
by our pathologist as well as three outside patholo-
gists), the patient never again showed any evidence
of dysplasia on 15 EGDs and 259 specimens. As of
this date, he is doing great.
Conclusion
The biologic influences controlling the fate of HGD
are not understood. Our two examples (unpub-
lished data) clearly demonstrate that not all patients
with HGD have predictable responses, and the best
management for one patient may not be the best
management for another patient. Research is needed
to discover the influencing factors, but, meanwhile,
each patient with flat HGD needs to be assessed as
an individual patient.
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Figure 1.
5. Is it possible to predict which patients




BE remains a premalignant metaplasia of the
esophageal mucosa with a spectrum of cellular
behavior ranging from ND to LGD to HGD to can-
cer (AdCa). Current follow-up recommendations
are usually ignored for (flat) HGD: follow-up ev-
ery three months with EGD and biopsy until HGD
disappears or develops into a lump and ablation
therapy with any of five modalities.
Objectives
To offer safe, feasible, and evidence-based
BE surveillance strategies comprising long-term
follow-up guidelines with which physicians as well
as patients can feel comfortable.
Methods
Our Veterans Association (VA) outpatient scope
room was opened in 1979. Esophagogastroduo-
denoscopies (EGDs) were performed by one of three
endoscopists using preestablished and agreed-upon
clinical criteria for (1) EGD indications, (2) defi-
nitions, and (3) biopsy technique. Locations, con-
figurations, and extent of BE and hiatal hernia
were recorded and mapped by hand on to one of
22 diagram figures that adjusted for hiatal hernia
(HH) size and shape. Attempts were made to biopsy
the squamo-columnar junction (SCJ) regardless of
its appearance. Biopsy specimens were taken as
follows:
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• Two for every 1 cm BE, or four for every 2 cm
of BE (one from each quadrant).
• Targeted biopsies were taken of irregular or sus-
picious areas.
• Biopsy specimens (for all 26 years) were read in
detail by one pathologist (GC).
Definitions
• BE: intestinal metaplasia (IM) from the tubular
esophagus or from the GE junction area IF the
biopsy contained, as one specimen, the squamo-
IM junction.
• Prevalent HGD or AdenoCa: diagnosis at the
first (or within 12 months of the first) EGD.
• Incident HGD or AdenoCa: diagnosis at least
one year after the first EGD.
• Surveillance: time period beginning one year
after the first EGD in patients with no current
or past HGD or AdenoCa.
Protocol
Patients were categorized according to the most
advanced lesion (e.g., HGD and AdCa occurring
together were considered AdenoCa) and remained
in the category until a more advanced lesion was
found.
• For LGD: biopsy repeated once at one to two
years and then every two to four years;
• For HGD: biopsy repeated at three-month in-
tervals for one year (“the hunt”);
• If no HGD was found on two consecutive biop-
sies, intervals became six months;
• After another year, intervals became 12 months,
until and unless HGD was again noted.
Results (unpublished data)
During the 26 years, 1,664 patients were found with
BE ranging from ND to AdenoCa:
• ND on first EGD (n = 644): not a single patient
with ND progressed to AdenoCa;
• LGD on first EGD (n = 968);
• 946 LGD (97.7%) remained with LGD (or
bounced: ND/HGD), but did not progress to
AdenoCa;
• 13 LGD (1.3%) progressed through HGD to
AdCa (incident AdenoCa from LGD through
HGD);
• 10 LGD (1.0%) progressed directly to AdCa (in-
cident AdenoCa from LGD without HGD);
• HGD on first EGD: (n = 51) (prevalent HGD);
• 43 HGD (84.3%) remained with HGD (or
bounced: ND/HGD), but did not progress to
AdenoCa; and
• 3 HGD (5.9%) progressed to AdenoCa (inci-
dent AdCa after The Hunt).
Discussion
Management strategies designed to detect Barrett’s
cancers must consider several factors:
1. AdenoCa rarely develops in patients with
Barrett’s and ND.
2. AdenoCa does develop in patients with a di-
agnosis of only LGD.
3. HGD found in flat Barrett’s should be fol-
lowed by the hunt.
4. With the one-year Hunt, it is guaranteed that
your life will be meaningful.
a. 10% of patients with flat HGD will be
harboring a Barrett’s cancer that will be
detected and cured by your wise decision
to employ the hunt.
b. In the 15 years following the hunt, an ad-
ditional 6% of patients with HGD found
at first EGD will have a Barrett’s can-
cer that will be detected and cured by
your wise decision to perform “post-
hunt” surveillance.
c. Thus, if we find flat HGD during the first
EGD, we can expect in the next 15 years
that 16% will have a Barrett’s cancer that
will be cured as a result of our wisdom
and intellectual prowess.
5. With the knowledge that ND is benign and
that LGD can precede both HGD and AdCa,
you can impress your patients with the fol-
lowing facts:
a. Surveillance during the next 15 years is
unlikely to detect anything meaningful if
you have ND, but we’ll do it anyway be-
cause I’m tired of talking about it.
b. Surveillance during the next 15 years will
detect curable AdCa in 2% of all patients
with any Barrett’s: dysplastic or nondys-
plastic.
c. Surveillance during the next 15 years will
detect curable AdCa in 2.5% of all patients
with dysplastic Barrett’s of LGD.
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d. Surveillance during the next 15 years will
detect curable AdCa in 3.0% of all patients
with dysplastic Barrett’s LGD and HGD.
Surveillance during the next 15 years will
detect curable AdCa in 19.0% of all pa-
tients who have HGD at any time.
6. Thirty of the 31 patients with AdCa detected
on our program were curable, including those
whose last EGD was three years earlier.
Conclusions
If the endoscopist has clearly visualized a flat Bar-
rett’s mucosa and has obtained appropriate biopsy
specimens:
1. The hunt, followed by surveillance, is a safe and
effective protocol for patients with flat HGD.
2. Patients with LGD (without HGD/AdCa) can
safely be followed with EGD at two to three
year intervals.
3. Patients with HGD should undergo the hunt,
followed by surveillance EGD.
4. Yearly EGD (for LGD) and quarterly EGD (for
HGD) is not necessary after the first intensive
year if the endoscopist has clearly visualized a
flat (no bumps) mucosa and has obtained ap-
propriate biopsy specimens.
5. Surgical resection for Barrett’s HGD is a thing
of the past.
6. Which biopsy protocol is most likely to
detect dysplasia in Barrett’s mucosa?
Sanjay Nandurkar
sanjay.nandurkar@med.monash.edu.au
BE is a chronic condition characterized by a change
in lining of esophageal mucosa from squamous ep-
ithelium to columnar metaplasia. The latter epithe-
lium can develop dysplasia, which can lead to the
development of adenocarcinoma. Thus, Barrett’s is
an important preneoplastic condition that confers a
30–50-fold increased risk of adenocarcinoma. The
incidence of adenocarcinoma of the esophagus has
increased significantly in the last two decades in the
Western world.
Periodic endoscopic and histological surveillance
has been recommended as a means to detect dys-
plasia or adenocarcinoma at an early stage, as in-
stituting therapy at this point confers survival ad-
vantage. Barrett’s segments can vary widely: some
can be only a few centimeters long (short segment
Barrett’s) and others can extend more than 10 cm.
Accurate sampling of mucosa to get a good rep-
resentative pathological perspective of the entire
Barrett’s segment can pose a challenge. Most gas-
troenterology societies recommend taking a biopsy
from four quadrants at 2 cm intervals. While
this is logistically easy for short segment Bar-
rett’s, this can be quite time consuming for long
segments.
A recent study from the Glasgow Royal Infirmary
analyzed the biopsy practice between two groups of
endoscopists; the surgeons adopted the systematic
4-quadrant approach in 1995, whereas the physi-
cians continued to take fewer nonsystematic biop-
sies. The mean number of biopsies taken per patient
was greater in the surgical group compared to the
physicians (16 vs. 4, respectively). And this was ev-
idenced by greater detection of LGD and HGD by
the surgeons compared with the physicians (LGD:
18.9% vs. 1.6%; HGD: 2.8% vs. 0%). Advanced can-
cer was seen in three cases in the physicians group
but none in the surgical group.14 This study under-
scores the importance of a systematic approach to
surveillance. Apart from not taking adequate biopsy
samples, the other significant issue is the lack of fol-
low up of many patients with BE. Data from a VA
center in the United States analyzed a cohort of 472
patients with Barrett’s between 1995 and 2005. They
found that two-thirds of patients (n = 305) had only
one endoscopy performed, and approximately 25%
of patients with LGD missed their surveillance in-
terval by more than six months.15
In spite of an adequate number of biopsies per
protocol, endoscopic sampling only examines a very
limited surface area. The standard biopsy forceps
can obtain a 1.9 mm biopsy (with a depth of 1
mm). Biopsy forceps with a larger cup (jumbo for-
ceps) can increase the surface area sampled (width=
3.3 mm, depth = 2 mm). Intuitively, it would ap-
pear more logical to use jumbo forceps to obtain
greater tissue mass for analysis. One small study has
shown improved dysplasia detection using jumbo
forceps, but larger studies are needed.16 There is
good evidence that has shown that mucosal irregu-
larity, nodules, and ulcers with the Barrett’s segment
are highly associated with the presence of dysplasia
and/or cancer. Thus, close scrutiny of the Barrett’s
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segment to identify surface irregularity and getting
targeted biopsies from those areas is extremely im-
portant before embarking on 4-quadrant biopsies,
lest those landmarks get obliterated by blood during
sampling.
The presence of dysplasia, especially HGD, por-
tends the presence of concomitant adenocarcinoma
or the possibility of cancer developing in the imme-
diate future. Thus, patients with HGD need closer
observation at frequent intervals. Although some
groups have campaigned for early resection in HGD
to avoid missing a prevalent cancer, the Seattle group
has shown quite convincingly that adequate biopsy
sampling at close time intervals does not lead to
missed cancers.17 They advocated taking 4-quadrant
biopsies at 1-cm intervals using jumbo forceps as
well as taking multiple biopsies from any macro-
scopic abnormality. They showed that in patients
with HGD who have a high probability of harbor-
ing cancer, their 1-cm-interval protocol detected
all cancers, whereas a 2-cm protocol would have
missed 50% of the cancers. The Cleveland group
performed a retrospective analysis and found that
in their hands the 1-cm protocol and the standard
2-cm protocol both performed badly and missed
30–40% of intramucosal cancers (although no
submucosal cancers escaped detection). However,
Cleveland study has been criticized by some as being
retrospective for proactively identifying and target-
ing macroscopic irregularities that the Seattle group
highlighted.
The use of acetic acid improves surface visual-
ization and is quick and easy to apply. Preliminary
data suggest that acetic acid target biopsies improve
detection of dysplasia compared to the standard 2-
cm protocol. Numerous investigators have evalu-
ated the use of chromoendoscopy (usually methy-
lene blue) to identify suspicious areas for targeted
biopsies. However, it appears to be highly opera-
tor dependent, and the published reports are highly
contradictory; hence, its use would difficult to ad-
vocate.
Newer imaging techniques such as narrow band
imaging (NBI) and Fujinon intelligent color en-
hancement (FICE) can provide improved visualiza-
tion of surface mucosa. There is a significant amount
of published literature that has shown improve-
ment in neoplasia detection using NBI technology. A
recent meta-analysis of eight studies that included
446 patients and 2,194 lesions showed that the sen-
sitivity and specificity for detection of HGD using
NBI was 0.96 and 0.94, respectively.18 Confocal laser
endomicroscopy (CLE) is a revolutionary technique
that images subcellular tissue in real time (virtual
biopsy). However, it samples only a highly limited
surface area, is time consuming, and early reports
to date have not shown it to be better than standard
biopsy protocol.
In summary, scheduled surveillance protocol
with 2-cm protocol for Barrett’s patients at aver-
age risk and 1-cm protocol (Seattle) for patients at
high risk shows the best outcome. Adequate visu-
alization of Barrett’s surface mucosa is critical to
identify mucosal irregularities which are associated
with HGD and or cancer. Targeted biopsies using
acetic acid and NBI and use of jumbo forceps to ob-
tain larger samples appears to be beneficial. Use of
chromoendoscopy cannot be routinely advocated,
except in certain institutions.
7. Can gastric atrophy be an explanation of
the inverse association of adenocarcinoma
with H. pylori infection?
Hala El-Zimaity
hala.el-zimaity@uhn.on.ca
Until the mid 1970s, adenocarcinoma was a rare
cancer type in the esophagus. Since then, the con-
tinuing decline in H. pylori infection in Western
populations has been associated with a marked in-
crease in GERD, BE, and EAC.19 The question to an-
swer here is, “can gastric atrophy be an explanation
of the inverse association of adenocarcinoma with
H. pylori infection?”
The explanation for the inverse association would
come from clinical trials. Epidemiologic data sug-
gest that a subset of H. pylori–infected patients
may experience a lower risk of Barrett’s carcinoma.
Many studies use serology biomarkers to screen pa-
tients for gastric atrophy. Serum pepsinogen I is an
indirect measure of corpus function. As PGI is se-
creted only by oxyntic glands, with advancing cor-
pus atrophy, PG1 goes down. A low sPGI is a sero-
logic marker of corpus atrophy. Most of Japanese
Barrett’s patients are H. pylori naı̈ve with high serum
pepsinogen levels.20 H. pylori infection was present
in four of 36 patients (11%) with Barrett’s and
in 80 of 108 controls (74%, P < 0.0001).20 In
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H. pylori–negative subjects, both serum pepsino-
gen I and pepsinogen II concentrations are sig-
nificantly higher in Barrett’s patients than in con-
trols (mean pepsinogen I: Barrett’s 51.0–14.0 ng/mL
vs. control 38.9–13.5 ng/mL, P = 0.0012; mean
pepsinogen II: Barrett’s 10.8–4.0 ng/mL vs. control
7.9–2.0 ng/mL, P = 0.0097). Thus, in Japan, an in-
verse association exists between low pepsinogen I
levels (a marker of advanced gastric atrophy) and
Barrett’s.20
Since 1969, Japanese physicians have used en-
doscopy to visualize changes in the gastric mucosa of
gastritis patients.21 Atrophic gastric mucosa is pale
yellowish in color, with transparent blood vessels,
and nonatrophic mucosa is homogeneously reddish
and smooth. The atrophic border is the boundary
between the antral and fundic glandular territories.
At endoscopy, the atrophic border is recognized by
discriminating between the differences in the color
and height of the gastric mucosa. Japanese physi-
cians incorporated the endoscopic atrophic border
in an endoscopic grading system for atrophy.21 Cor-
pus atrophy begins at atrophic border (antrum–
corpus border) in particular the incisura and ex-
tends proximally more rapidly up the lesser curve
than the greater curvature. Atrophy in corpus biop-
sies high on the greater curvature are among the last
to show atrophy. Following the Japanese endoscopic
grading system, atrophy limited to the lesser curve
is “closed.” Atrophy extending high on the greater
curvature is “open.” Kim et al. showed the endo-
scopic grading of atrophic gastritis is inversely asso-
ciated with gastroesophageal reflux and gastropha-
ryngeal reflux.22 GERD and gastropharyngeal reflux
disease was significantly lower in the open type (ad-
vanced gastric atrophy) than in the closed type (less-
advanced gastric atrophy) (P < 0.001, P = 0.012,
respectively).22
The endoscopic grading system shows a good cor-
relation with histological evaluation. Gastric back-
ground mucosa in patients with distal esophageal
cancer has a higher prevalence of nonatrophic gas-
tric mucosa when compared to gastric background
mucosa in patients with distal gastric cancer. The
latter are always associated with advanced gastric
atrophy.23 Altogether, studies suggest that gastric
atrophy associated with H. pylori infection may
be responsible for the inverse association between
H. pylori infection and esophageal disease.
8. What are the arguments against the




H. pylori infection has been associated with a de-
creased risk of GERD and related diseases. No clini-
cal trials are available to answer this question. In gen-
eral, epidemiological studies have found an inverse
relationship between H. pylori infection and/or Cag-
A–positive strains and BE and adenocarcinoma of
the esophagus, but these findings have not been con-
sistent in all studies, and two meta-analyses have
come out with different conclusions. One, reported
in 2007, concluded that in patients with BE there
were inverse relationships with H. pylori infection
overall and with Cag-A–positive strain (OR, 0.64;
95% CI, 0.43–0.94; OR, 0.39; 95% CI, 0.21–0.76,
respectively).24 However, a most recent one with
a higher number of studies25 concluded that there
was no association between H. pylori infection and
BE (Fig. 2). The overall prevalence of H. pylori in-
fection between BE and controls was 42.9% versus
43.9% (OR = 0.74, 95% CI 0.40–1.37), but with sig-
nificant heterogeneity. Further analyses were con-
ducted based on the type of controls used as ref-
erence group. In nine studies, the prevalence of
H. pylori infection was lower in BE than in en-
doscopically normal healthy controls (23.1% vs.
42.7%, OR = 0.50, 95% CI 0.27–0.93) with sig-
nificant heterogeneity observed between studies. In
contrast, H. pylori infection was significantly in-
creased in BE patients in the three studies using
healthy blood donors as “normal controls” (71.2%
vs. 48.1%, OR = 2.21, 95% CI 1.07–4.55).
The question then may rely on who is the appro-
priate control for this type of studies. In principle,
patients undergoing endoscopy for different indi-
cations should be excluded as controls since they
may suffer of diseases linked to H. pylori infec-
tion. On the other hand, blood donors may rep-
resent a selected population. Controls should be
as close as possible to the general healthy popu-
lation and should be matched by age and sex, since
H. pylori infection prevalence is age dependent, and
BE is more frequent in males. Other factors that
should be considered when interpreting these stud-
ies are geographical/race differences, definitions of
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Figure 2. Meta-analysis of the prevalence of Helicobacter pylori in patients with BE versus controls.25 With permission from
Macmillan Publishers Ltd.
BE, using a retrospective versus a prospective ap-
proach, and the diagnostic tests used for H. pylori
infection. Furthermore, confounding variables can
explain negative results. No clear mechanistic expla-
nation is available. The most frequent one has been
linked to a reduced acid output due to the presence
of corpus gastritis and different degrees of atrophy
in H. pylori–infected individuals, but a negative as-
sociation has been found in patients with negative
atrophic gastritis. Also, H. pylori infection may in-
crease gastric secretion in patients with antral gas-
tritis.26,27 Therefore, due to the low quality of most
studies and the lack of an appropriate mechanistic
explanation, we cannot conclude that there is a rela-
tionship between H. pylori and BE. Well-performed,
larger studies with appropriate controls matched by
age and sex should be conducted.
9. Should decrease of PPI efficacy
following eradication of H. pylori be
considered in the treatment of BE?
Angel Lanas
alanas@unizar.es
It has been shown that PPIs induce a higher de-
gree of acid inhibition in H. pylori–infected in-
dividuals, which provides higher healing rates in
erosive esophagitis patients treated with PPIs.28 Pa-
tients with BE are recommended to be treated
with high-dose PPI to reduce gastric acid and re-
duce esophageal acid exposure as much as possi-
ble. Patients with BE can undergo H. pylori erad-
ication under different circumstances. This may
reduce the capacity of PPIs to inhibit acid gas-
tric acid secretion. However, no studies have ad-
dressed specifically this question in BE patients.
There are no studies to define whether H. py-
lori eradication worsens or improves BE after
H. pylori eradication. In one study, which included
24 cases of short-segment BE within a sample of
82 patients with peptic ulcer disease, it was shown
that after H. pylori eradication, there were six new
cases of short-segment BE after a mean follow-up
of 24 months.29 Another study showed that H. py-
lori infection did not influence esophageal acid re-
flux and symptoms in patients with BE, either at
baseline or during low, as well as profound, acid
suppressive therapy. The authors concluded that
the dose of acid suppression does not have to be
titrated upon H. pylori status in GERD patients
(Fig. 3).30 A systematic review of 27 studies con-
cluded that H. pylori eradication in peptic ulcer
patients does not induce esophagitis or worsen
302 Ann. N.Y. Acad. Sci. 1232 (2011) 292–308 c© 2011 New York Academy of Sciences.
Appelman et al. Barrett’s esophagus: natural history
Figure 3. Individual values of percentage intraesophageal pH
< 4 per 24 hours in Helicobacter pylori –negative and H. py-
lori–positive Barrett’s esophagus patients at baseline and dur-
ing therapy with omeprazole 40 mg b.d. at three months.30 With
permission from John Wiley & Sons.
GERD symptoms.31 Also, it has been shown that
patients with established GERD did not require in-
creased doses of PPI after H. pylori eradication.32
Therefore, although no studies have specifically
addressed this question in BE patients, indirect ev-
idence suggests that a potential decrease of PPI
efficacy should not preclude the indication for H.
pylori eradication, and that this should not be of
concern for patients with BE.
10. Is surgical treatment likely to modify
the progression of natural history of BE?
Paolo Parise
p.parise@ao-pisa.toscana.it
The American College of Gastroenterology 2008
guidelines defines BE as a “change in distal
esophageal epithelium of any length that can be
recognized as columnar type mucosa at endoscopy
and is confirmed to have intestinal metaplasia by
biopsy of the tubular esophagus.”33 Patients with
long-segment BE have a 30–125-fold increased
risk of developing esophageal cancer,34,35 but the
real natural history of the sequence metaplasia–
dysplasia–carcinoma is still unclear, because most
of these patients undergo surgical or medical ther-
apy. However, in this multistep sequence, dyspla-
sia represents the best marker of the development
of adenocarcinoma of the gastro-esophageal junc-
tion. In this cascade, some steps are thought to be
very rarely reversible (BE normal epithelium) or
never (adenocarcinoma–dysplasia), but others can
and do regress. This represents the rationale for
the surveillance and medical or surgical treatment
of BE.
In a prospective study in 1999, Weston and col-
leagues followed 108 patients affected by BE and
who were treated with PPI for a mean period of
40 months. At baseline endoscopy, they found 80
patients with ND, 20 with LGD, and eight with
HGD. Among the nondysplastic group, 2.5% pro-
gressed to cancer and 28.7% progressed to LGD with
a subsequent regression rate of 78.2%. In the LGD
group, 65% of patients regressed to ND, but 20%
progressed to HGD, subsequently developing cancer
or multifocal HGD in 50% cases and nondysplastic
BE in the remaining 50% cases. Patients presenting
with HGD developed cancer or multifocal HGD in
62.5% cases and regressed to LGD or ND in the
other cases.36
In a retrospective study from the Netherlands,
Hage and colleagues analyzed 105 patients affected
by at least 3 cm BE without HGD or cancer at first en-
doscopy for a mean follow-up period of 12.7 years.
LGD was present in 11 patients at entry endoscopy.
At the end of follow-up, 6% patients had developed
adenocarcinoma, which equals one cancer case per
221 patient-year or 0.45% per year. Tumors were in-
terestingly diagnosed in a very wide range of time,
from 4.6 to 15.9 years after index endoscopy. HGD
was diagnosed in 5% of patients, which equals one
cancer case per 266 patient-year or 0.38% per year.
Similarly, diagnosis was made in wide period, rang-
ing from 0.6 to 18.9 years. Regression from LGD
to nondysplastic Barrett’s epithelium was observed
in 50% cases, but a progression to HGD was ob-
served in 25% cases. A trend towards cancer de-
velopment was observed for increasing lengths of
BE.37 But, with logistic regression analysis, other
risk factors have been identified for development
of multifocal HGD or adenocarcinoma: dysplasia at
first endoscopy (P < 0.001), >3 cm hiatal hernia
(P < 0.02), presence of dysplasia at any time dur-
ing follow-up (P < 0.03), and Barrett’s epithelium
>2 cm (P < 0.009).36
The rationale of laparoscopic antireflux surgery
in patients affected by BE is to prevent the pro-
gression to dysplasia–carcinoma and even to induce
the regression to a nondysplastic Barrett’s epithe-
lium or a non metaplastic epithelium. It is com-
monly accepted that, once established, BE doesn’t
regress. This conclusion is supported by some endo-
scopic data that show no change in the length of the
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columnar-lined epithelium under therapy,38 but in
a study on 77 patients treated with antireflux surgery
versus 14 patients treated with PPI, Gurski et al. ob-
served a complete regression of the metaplastic ep-
ithelium in 36.4% of surgical patients versus 7.1%
of medical patients (P < 0.03). Authors also ev-
idenced that regression happened only in patients
with short segment BE.39 Even better results were re-
ported in a recent study on 125 patients with short
segment BE treated with laparoscopic Nissen fundo-
plication, duodenal switch, or duodenal diversion.
Regression to nonmetaplastic mucosa was observed
in 61% patients of the Nissen group, and 64% and
65%, respectively, in the other two groups.40 Antire-
flux surgery also seems to be effective in inducing
regression from LGD and preventing progression
to HGD or cancer. Hofstetter and colleagues evalu-
ated the long-term outcome (five years) of antireflux
surgery in 97 patients affected by BE. LGD regressed
to nondysplastic Barrett’s in 44% cases and intestinal
metaplasia was lost, regressing to cardiac mucosa, in
14%. No patient developed HGD or cancer in 410
patient-years of follow-up, but LGD developed in
6% patients.41 In 2003, Parrilla published the results
of a randomized study comparing medical and sur-
gical treatment of BE patients. In the medical group,
2 of 3 patients regressed from LGD to ND, and in the
surgical group, 5 of 5 regressed. In the medical arm,
dysplasia de novo appeared in 8 of 40 patients (20%);
two of these developed HGD. In the surgical arm,
3 of 53 patients (6%) developed dysplasia de novo,
and two of these subsequently progressed to HGD,
but these two showed a pH-metric recurrence of
gastroesophageal reflux. No statistically significant
differences were found between these two groups.
If the patients with pH-metric failure are excluded,
dysplasia de novo appeared only in 2% of patients
and the surgical group showed a statistically sig-
nificant difference respect the medical group (P <
0.05). The rate of malignancy was 0.8% per year in
the medical group and 0.5% in the surgical group.42
Similar good results were obtained in a little study
from our institution, where medical (19 patients)
versus surgical (16 patients) treatment were com-
pared in LGD patients at 18 months follow-up. We
observed a regression rate of 63.2% in the medical
arm versus a 93.8% in the surgical arm (P = 0.047).
The association between treatment and remission of
LGD was examined using multiple logistic regres-
sion; laparoscopic Nissen fundoplication was the
only variable associated with the probability of re-
mission of LGD.43
These apparently better results of surgery respect
medical therapy could be explained by the fact that
the esophageal mucosa exposure to duodeno-gastric
refluxate is higher in patients with BE and with dys-
plasia44 and PPI are not able to block bile reflux;
moreover, we know that even under PPI therapy
about 60% patients have pathological esophageal
exposure to bile, in a weakly acid environment that
promotes the deconjugation of bile-salts.45 Unfor-
tunately, these results are not completely confirmed
by large meta-analysis of the literature.46,47 In fact,
surgically treated patients demonstrated a higher
incidence of regression from LGD to Barrett’s ep-
ithelium (15.4%) when compared with medically
treated patients (1.9%). Even when only controlled
studies were analyzed, the probability of developing
regression was greater in the surgically treated group
(6.5% vs. 0.5%, P = 0.024).
The largest difference between surgical and med-
ical therapy was demonstrated in the probability of
regression from nondysplastic BE to normal squa-
mous epithelium (17% vs. 0.4%). But, in regard
of incidence of EA, when data from all included
studies are pooled, the median incidence of can-
cer was 2.8 cases per 1,000 patient-years among
the surgical group and 6.3 in the medical group
(P = 0.034). When data from only controlled stud-
ies were pooled, the median incidence of adeno-
carcinoma in the surgical group did not signifi-
cantly differ from that of the medical group: 4.8
cases per 1,000 patient-years versus 6.5, respectively
(P = 0.32).
These conflicting results between the risk of can-
cer development and induction of regression could
be explained with the fact that cellular and genetic
alterations leading to adenocarcinoma may have al-
ready occurred before an antireflux procedure was
performed; thus some cancers, particularly those
that present during the first few postoperative years,
probably do not represent progression of the disease.
Even though antireflux surgery seems to better
promote regression of BE or dysplasia than med-
ical therapy, it has not demonstrably reduced the
incidence rate of adenocarcinoma, and therefore
cannot be currently recommended as an antineo-
plastic procedure. Nevertheless, antireflux proce-
dures should be proposed as a therapeutic alter-
native to all patients affected by BE with or without
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associated dysplasia, thus balancing the risks and
benefits for each patient.
11. Is trimodal esophageal imaging
(HRE-FI-NBI) the best tool for
enhancement of detection of early
neoplasia in Barrett’s patients?
René Lambert
lambert@iarc.fr
Columnar metaplasia in the esophagus (Barrett’s)
occurs in relation to esophageal reflux and obesity
in the young age. Three distinct types of gastric
epithelium may develop in the distal esophagus: a
cardiac type with mucous epithelial cells, a fundic
type with chief and oxyntic cells, and an intesti-
nal type with goblet cells and enterocytes with a
brush border. The prevalence of Barrett’s is higher
in Caucasian males of Western countries; however,
it has been overestimated, and based on a Swedish
population of endoscopies performed in adults, it
is now estimated at 1.6%. Multiple studies confirm
an increased risk of adenocarcinoma in columnar
metaplasia of the esophagus, but it has also overes-
timated, and recent evaluations account for one case
per 200 patient-years. The risk has been correlated
with the presence of intestinal cells in the metaplas-
tic segment. However, recent studies conducted in
the United States have shown that intestinal cells are
found in only 48% of cases of Barrett’s, and a study
of small esophageal resected carcinomas has shown
that the tumor develops more often (70%) in the
vicinity of a cardiac type of epithelium. The risk of
cancer is the same in the presence or absence of in-
testinal cells in the metaplastic segment; therefore,
endoscopic exploration should aim to detect dys-
plasia rather than the intestinal type of epithelium.
In Western countries, attention given to the de-
tection of early cancer in BE is justified by an in-
creasing incidence of EA in recent decades;48 as
an example, the annual variation reaches +8.6%
in men in the SEER registries of the United States
during 1973–1995, but the worldwide incidence of
adenocarcinoma is still very low as compared to that
of squamous cell cancer in the esophagus. Overall,
detection of early esophageal neoplasia in asymp-
tomatic persons aims for curative treatment by en-
doscopic resection or by radiofrequency. As a rule,
early neoplasia in the metaplastic mucosa of a BE
is often missed during endoscopy, even with the
help of chromoscopy, when a dye solution is pro-
jected at the surface of the mucosa (indigocarmine,
methylene blue, or acetic acid). The poor efficacy
of targeted biopsies explains the recommendation
to adopt the time-consuming Reid protocol, with
blind or random biopsies performed in quadrants
at each length of 1 cm in the segment with columnar
metaplasia.
In recent years, the dramatic progression in endo-
scopic imaging, and the cumulative impact of high
resolution imaging (HRE), magnification, autoflu-
orescence spectroscopy (AFI), and image processing
modifies the diagnostic strategy of neoplasia in BE.
1. High-resolution imaging depends on the in-
creased number of pixels in the charged cou-
pled device (CCD) receiving the efferent pho-
tons and on the high (1,080 lines) definition of
the image transmitted to the TV receptor.
2. Magnification with an optical zoom at a power
of ×60 or ×80 describes with precision the mi-
croarchitecture of surface epithelium (pit pat-
tern) and subepithelial capillaries (vascular pat-
tern). An electronic zoom may also contribute
to magnification.
3. Autofluorescence imaging requires a specific ma-
terial: the AFI system proposed by Olympus
Medical Systems consists of a light source
(XCLV-260HP), a processor (XCV-260HP), a
video monitor, and a dedicated videoendo-
scope (XCF-Q240FAI), which incorporates two
CCDs, one for autofluorescence, the other for
white light. In autofluorescence, the excitation
light (390–470 nm) is provided by a rotation
filter on the light source. The resulting image is
artificially colored to green. A normal mucosa
emits a bright autofluorescence and is colored in
green. Fluorophores in the tumor absorb aut-
ofluorescence; the lesion appears in the com-
plementary color of green–magenta. However,
false-positive reactions in magenta are com-
mon.
4. Image processing with the NBI technique of
Olympus is based on the restriction of the af-
ferent light in two channels (blue and green);
in the efferent image the micro-architecture of
the epithelial crest is enhanced, and the subep-
ithelial capillaries have greater contrast. Other
methods in image processing have been devel-
oped by Fujinon (FICE) and Pentax (i-scan).
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The increased efficacy of HRE endoscopy in white
light combined to NBI has been stressed; both
are proposed as red flag techniques for the detec-
tion of neoplasia in Barrett’s.49,50 Recently, a fur-
ther progress in sensitivity and specificity is linked
to the trimodal technology, combining HRE, AFI,
and NBI, with or without magnification.51,52 This
protocol is proposed in a joint venture by endoscopy
units based in the Netherlands (Amsterdam) and
England (Manchester). The trimodal protocol sig-
nificantly increases the sensitivity of HRE and more
positive results are found. In addition, NBI reduces
the false-positive rate of HRE + AFI from 71% to
48%; however, it is concluded that this protocol can-
not substitute for the blind and random biopsies
protocol in BE.52
In conclusion, the trimodal protocol requires spe-
cialized materials, is restricted to some reference
centers, and, in Western countries, random biop-
sies are still recommended in asymptomatic patients
with BE for the detection of neoplasia. However,
in those countries, not enough room is attributed
to magnification. Currently, in Japan, the detection
of suspicious areas at the surface of the mucosa is
completed by characterization through categories
of the pit pattern and vascular pattern, and the best
method of detection of flat areas of neoplasia re-
lies on a bimodal HRE-NBI protocol coupled with
magnification. Both protocols are currently avail-
able in this country with video-endoscopes and de-
serve to be spread around the world. Exploration of
BE should rely on a protocol ensuring characteri-
zation after detection, while targeted biopsies could
replace random biopsies.
12. The essential importance of natural
history for the wise management of HGD
Helen M. Shields
hshields@caregroup.harvard.edu
HGD is not a fixed, well-defined entity. This is a ma-
jor problem to address in the management of HGD
in BE. Poor interobserver reproducibility is present
in the diagnosis of HGD even when excellent pathol-
ogists, experienced in reading gastrointestinal biop-
sies, focus on diagnosing HGD on Barrett’s slides
from Barrett’s patients.53 Dr. Maru from the M.D.
Anderson Cancer Center notes that 41% of outside
cases called “HGD” are classified as adenocarcinoma
by their group of pathologists.53 It is important to
recognize this fact in making a decision about what
is the best treatment for HGD.
Two very divergent studies have assessed the
risk of HGD in BE patients turning into
adenocarcinoma.54,55 In the Hines VA study, Schnell
et al. noted 16% of patients evolving to adenocarci-
noma over a follow-up interval of seven years and
three months of surveillance endoscopies.55 On the
other hand, Reid’s group at the University of Wash-
ington noted that 59% of their HGD patients had
developed adenocarcinoma at the five-year time in-
terval.54 This marked divergence in the evolution of
HGD to adenocarcinoma leads to significant doubt
about the reproducibility of the diagnosis of HGD
as supported by Maru’s observations above.53 What
should be done for patients with HGD that has
been verified by at least two experienced pathol-
ogists? The most effective and least harmful therapy
should be recommended. Esophagectomy has tradi-
tionally been associated with significant morbidity
and mortality. It is currently reserved for patients
who are not considered candidates for less inva-
sive, but potentially curative therapies, such as pho-
todynamic therapy, endoscopic mucosal resection,
and/or radiofrequency ablation.56,57 Photodynamic
therapy’s relatively high rate of stricture formation
and photosensitivity have limited its role now that
other modalities are available.
Ell et al. pointed out the feasibility of endoscopic
mucosal resection for HGD and early cancer in 64
BE patients with early esophageal cancer or HGD.56
The best evidence for cure available at present is the
use of endoscopic mucosal resection.56 Another ex-
cellent endotherapy is radiofrequency ablation. The
results reported in the 2009 New England Journal
of Medicine paper from Shaheen et al. showed that
the radiofrequency ablation method has its greatest
benefit in patients with HGD. Patients were ran-
domly assigned to receive the actual treatment or a
sham procedure. Eradication of HGD was found in
81% of the group receiving the therapy.57 Compared
to historical reports of the natural history of BE,
ablation may be associated with a reduction in can-
cer incidence. But heterogeneous studies limit the
comparison. A frequently asked question is whether
radiofrequency ablation should be added to endo-
scopic mucosal resection to improve follow-up re-
sults. The answer is not known at present. Also, the
role of laparoscopic or traditional surgery to cure
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an EA has not been compared to endoscopic mu-
cosal resection or radiofrequency ablation to date
in a randomized controlled trial. These prospective
studies are needed.
In summary, the wise management of HGD is
based on understanding that there is variability in
the diagnosis of HGD by pathologists. At present,
endoscopic mucosal resection therapy with or
without radiofrequency ablation appears to be
reasonable therapy for HGD or early esophageal
carcinoma. Research data also favor the use of ra-
diofrequency ablation compared to photodynamic
therapy because of fewer complications and better
efficacy. However, neither endoscopic mucosal re-
section nor radiofrequency ablation has been stud-
ied in randomized controlled trials and compared
to surgical therapy. Long-term follow-up data are
needed for all forms of therapy.
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